Revised SPC: Cabozantinib (Cabometyx) tablets

License extended to cover use in combination with nivolumab for the first-line treatment of advanced renal cell carcinoma and warning added of hepatoxicity with use of this combination resulting in higher frequencies of Grades 3 & 4 ALT and AST elevations.

Source:

electronic Medicines compendium